Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

hypertension - strategy - non diabetic patients  

hypertension - strategy - all type of patients  


Related trials

Cardio-Sis, 2009 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCORD blood pressure, 2008 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

REIN-2, 2005 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AASK, 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

Toto, 1995 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

HOT, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

MDRD, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie



See also:

  • All hypertension clinical trials
  • All clinical trials of strategy
  • All clinical trials of more intensive blood pressure lowering strategie
    		•  

    Toto study, 1995

    Treatments

    Studied treatment strict blood pressure control (DBP 65 to 80 mm Hg)
    Control treatment usual blood pressure control (DBP 85 to 95 mm Hg)
    Treatments description
    Achieved systolic blood 133/138 
    Achieved diastolic blood pressure 81/87 

    Patients

    Patients non-diabetic patients (age 25 to 73) with long-standing hypertension (DBP > or = 95 mm Hg), chronic renal insufficiency (GFR < or = 70 m/min/1.73 m2) and a normal urine sediment

    Method and design

    Randomized effectives 42 / 35 (studied vs. control)
    Blinding open
    Primary endpoint GFR slope


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    End stage renal disease

    7 / 42
         2 / 35
         classic 2,92 [0,65;13,15]

    All cause death

    1 / 42
         0 / 35
         classic 4,17 [0,06;298,20]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 1 / 42 (2,4%) 0 / 35 (1,4%) 1,67 [0,06;48,22]   11040 
    End stage renal disease 7 / 42 (16,7%) 2 / 35 (5,7%) 2,92 [0,65;13,15]   11040 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    End stage renal disease 16,67% 5,71% 11,0%


    Reference(s)

    Trials register # NA
    • Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.. Kidney Int 1995;48:851-9
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend